PURPOSE: To assess survival, local control and toxicity using fractionated stereotactic conformal radiotherapy (FSCRT) boost and temozolomide in high-grade gliomas (HGGs). PATIENTS AND METHODS: Patients affected by HGG, with a CTV(1)(clinical target volume, representing tumor bed ± residual tumor + a margin of 5 mm) ≤ 8 cm were enrolled into this phase II study. Radiotherapy (RT, total dose 6,940 cGy) was administered using a combination of two different techniques: three-dimensional conformal radiotherapy (3D-CRT, to achieve a dose of 5,040 or 5,940 cGy) and FSCRT boost (19 or 10 Gy) tailored by CTV(1)diameter (≤ 6 cm and > 6 cm, respectively). Temozolomide (75 mg/m(2)) was administered during the first 2 or 4 weeks of RT. After the end of RT, temozolomide (150-200 mg/m(2)) was administered for at least six cycles. The sample size of 41 patients was assessed by the single proportion-powered analysis. RESULTS: 41 patients (36 with glioblastoma multiforme [GBM] and five with anaplastic astrocytoma [AA]) were enrolled; RTOG neurological toxicities G1-2 and G3 were 12% and 3%, respectively. Two cases of radionecrosis were observed. At a median follow-up of 44 months (range 6-56 months), global and GBM median overall survival (OS) were 30 and 28 months. The 2-year survival rate was significantly better compared to the standard treatment (63% vs. 26.5%; p < 0.00001). Median progression-free survival (PFS) was 11 months, in GBM patients 10 months. CONCLUSION: FSCRT boost plus temozolomide is well tolerated and seems to increase survival compared to the standard treatment in patients with HGG.
PURPOSE: To assess survival, local control and toxicity using fractionated stereotactic conformal radiotherapy (FSCRT) boost and temozolomide in high-grade gliomas (HGGs). PATIENTS AND METHODS: Patients affected by HGG, with a CTV(1)(clinical target volume, representing tumor bed ± residual tumor + a margin of 5 mm) ≤ 8 cm were enrolled into this phase II study. Radiotherapy (RT, total dose 6,940 cGy) was administered using a combination of two different techniques: three-dimensional conformal radiotherapy (3D-CRT, to achieve a dose of 5,040 or 5,940 cGy) and FSCRT boost (19 or 10 Gy) tailored by CTV(1)diameter (≤ 6 cm and > 6 cm, respectively). Temozolomide (75 mg/m(2)) was administered during the first 2 or 4 weeks of RT. After the end of RT, temozolomide (150-200 mg/m(2)) was administered for at least six cycles. The sample size of 41 patients was assessed by the single proportion-powered analysis. RESULTS: 41 patients (36 with glioblastoma multiforme [GBM] and five with anaplastic astrocytoma [AA]) were enrolled; RTOG neurological toxicitiesG1-2 and G3 were 12% and 3%, respectively. Two cases of radionecrosis were observed. At a median follow-up of 44 months (range 6-56 months), global and GBM median overall survival (OS) were 30 and 28 months. The 2-year survival rate was significantly better compared to the standard treatment (63% vs. 26.5%; p < 0.00001). Median progression-free survival (PFS) was 11 months, in GBM patients 10 months. CONCLUSION: FSCRT boost plus temozolomide is well tolerated and seems to increase survival compared to the standard treatment in patients with HGG.
Authors: Robert Cardinale; Minhee Won; Ali Choucair; Michael Gillin; Arnab Chakravarti; Christopher Schultz; Luis Souhami; Allan Chen; Huong Pham; Minesh Mehta Journal: Int J Radiat Oncol Biol Phys Date: 2006-06-05 Impact factor: 7.038
Authors: June L Chan; Susan W Lee; Benedick A Fraass; Daniel P Normolle; Harry S Greenberg; Larry R Junck; Stephen S Gebarski; Howard M Sandler Journal: J Clin Oncol Date: 2002-03-15 Impact factor: 44.544
Authors: S W Lee; B A Fraass; L H Marsh; K Herbort; S S Gebarski; M K Martel; E H Radany; A S Lichter; H M Sandler Journal: Int J Radiat Oncol Biol Phys Date: 1999-01-01 Impact factor: 7.038
Authors: W J Curran; C B Scott; J Horton; J S Nelson; A S Weinstein; A J Fischbach; C H Chang; M Rotman; S O Asbell; R E Krisch Journal: J Natl Cancer Inst Date: 1993-05-05 Impact factor: 13.506
Authors: Ashwatha Narayana; John G Golfinos; Ingeborg Fischer; Shahzad Raza; Patrick Kelly; Erik Parker; Edmond A Knopp; Praveen Medabalmi; David Zagzag; Patricia Eagan; Michael L Gruber Journal: Int J Radiat Oncol Biol Phys Date: 2008-10-01 Impact factor: 7.038
Authors: Brigitta G Baumert; Johannes Lutterbach; René Bernays; J Bernard Davis; Frank L Heppner Journal: Radiother Oncol Date: 2003-05 Impact factor: 6.280
Authors: M J R Runge; M Maarouf; S Hunsche; M Kocher; M I Ruge; F El Majdoub; H Treuer; R-P Mueller; J Voges; V Sturm Journal: Strahlenther Onkol Date: 2012-02-22 Impact factor: 3.621
Authors: M D Piroth; M Pinkawa; R Holy; J Klotz; S Schaar; G Stoffels; N Galldiks; H H Coenen; H J Kaiser; K J Langen; M J Eble Journal: Strahlenther Onkol Date: 2012-02-22 Impact factor: 3.621
Authors: A Theelen; J Martens; G Bosmans; R Houben; J J Jager; I Rutten; P Lambin; A W Minken; B G Baumert Journal: Strahlenther Onkol Date: 2011-12-24 Impact factor: 3.621
Authors: Piernicola Pedicini; Alba Fiorentino; Vittorio Simeon; Paolo Tini; Costanza Chiumento; Luigi Pirtoli; Marco Salvatore; Giovanni Storto Journal: Strahlenther Onkol Date: 2014-04-04 Impact factor: 3.621